HC Wainwright & Co. Reiterates Buy on Lyra Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Lyra Therapeutics (NASDAQ:LYRA) and maintained a $12 price target.

March 22, 2024 | 10:40 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lyra Therapeutics has been reiterated with a Buy rating and a $12 price target by HC Wainwright & Co. analyst Matthew Caufield.
The reiteration of a Buy rating and maintenance of a $12 price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in LYRA's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100